MGNX MACROGENICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1125345 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.8%
TTM net income YoY32.1%
TTM EPS YoY33.9%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-70.2%
Net margin-45.4%
FCF margin-36.4%
EBITDA margin-66.4%
Returns
ROE-111.8%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets92.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage-4.52x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $149.50M | $149.96M |
| Cost of revenue | $0 | $847,000 |
| Gross profit | $149.50M | $149.12M |
| R&D expense | $147.17M | $177.19M |
| SG&A expense | $39.16M | $71.05M |
| Operating income | -$72.84M | -$110.58M |
| Interest expense | $8.51M | $1.11M |
| Pretax income | -$75.29M | -$66.02M |
| Income tax | -$672,000 | $944,000 |
| Net income | -$74.62M | -$66.97M |
| EBITDA | -$65.67M | -$103.04M |
| EPS (basic) | -1.18 | -1.07 |
| EPS (diluted) | -1.18 | -1.07 |
| Weighted avg. shares (diluted) | 63.16M | 62.62M |
| Balance sheet | ||
| Cash & equivalents | $57.22M | $182.84M |
| Receivables | $427,000 | $4.31M |
| Inventory | $7.91M | $0 |
| Current assets | $219.94M | $217.49M |
| PP&E, net | $2.10M | $18.10M |
| Total assets | $256.85M | $261.65M |
| Current liabilities | $43.12M | $55.53M |
| Total liabilities | $201.25M | $145.60M |
| Shareholders' equity | $55.59M | $116.06M |
| Shares outstanding | 63.32M | 62.82M |
| Cash flow statement | ||
| Operating cash flow | -$81.04M | -$68.37M |
| Capital expenditure | $1.91M | $3.71M |
| Free cash flow | -$82.95M | -$72.08M |
| Investing cash flow | -$114.10M | $149.30M |
| Financing cash flow | $69.51M | $960,000 |
| Depreciation & amortization | $7.17M | $7.54M |
| Stock-based compensation | $14.29M | $29.44M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.